Protocol Ledger

NCT04867837 · Phase III · TERMINATED

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

Interventional Phase III clinical trial protocol NCT04867837 sponsored by Octapharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-01 Enrollment: 100 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04867837
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04867837
Protocol FieldVerified Registry Value
NCT IdentifierNCT04867837
Consolidated Lead SponsorOctapharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment100 participants (ACTUAL)
Registered Start Date2021-09-01
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI